

WEBVTT

NOTE duration:"00:02:10.2830000"

NOTE recognizability:0.852

NOTE language:en-us

NOTE Confidence: 0.8521029

00:00:00.000 --> 00:00:02.520 My name is Mandar Mazumdar name,

NOTE Confidence: 0.8521029

00:00:02.520 --> 00:00:04.560 a medical oncologist at Smilow Cancer

NOTE Confidence: 0.8521029

00:00:04.560 --> 00:00:06.360 Hospital, scientific director of the

NOTE Confidence: 0.8521029

00:00:06.360 --> 00:00:07.820 Center for Gastrointestinal Cancers

NOTE Confidence: 0.8521029

00:00:07.820 --> 00:00:10.169 at the Yale Cancer Center and a

NOTE Confidence: 0.8521029

00:00:10.169 --> 00:00:11.729 cancer biologist in the Department

NOTE Confidence: 0.8521029

00:00:11.788 --> 00:00:13.428 of Genetics at Yale University,

NOTE Confidence: 0.8521029

00:00:13.430 --> 00:00:14.615 School of Medicine.

NOTE Confidence: 0.8521029

00:00:14.615 --> 00:00:16.985 I treat patients admitted to the

NOTE Confidence: 0.8521029

00:00:16.985 --> 00:00:19.059 medical oncology service at Smilow

NOTE Confidence: 0.8521029

00:00:19.059 --> 00:00:21.471 Cancer Hospital and have a special

NOTE Confidence: 0.8521029

00:00:21.537 --> 00:00:23.907 clinical focus in pancreatic cancer.

NOTE Confidence: 0.8521029

00:00:23.910 --> 00:00:26.382 Pancreatic cancer remains one of the

NOTE Confidence: 0.8521029

00:00:26.382 --> 00:00:29.060 greatest challenges we have in cancer care.

NOTE Confidence: 0.8521029

00:00:29.060 --> 00:00:30.412 Although we've improved outcomes

NOTE Confidence: 0.8521029

00:00:30.412 --> 00:00:33.269 in a variety of cancers due to the

NOTE Confidence: 0.8521029

00:00:33.269 --> 00:00:34.801 development of new chemotherapies

NOTE Confidence: 0.8521029

00:00:34.801 --> 00:00:37.120 new targeted therapies that go after

NOTE Confidence: 0.8521029

00:00:37.120 --> 00:00:38.564 specific mutations within tumors

NOTE Confidence: 0.8521029

00:00:38.564 --> 00:00:40.798 and new therapies that target cancer

NOTE Confidence: 0.8521029

00:00:40.798 --> 00:00:42.768 through harnessing the immune system

NOTE Confidence: 0.8521029

00:00:42.768 --> 00:00:44.996 outcomes and pancreatic cancer have only

NOTE Confidence: 0.8521029

00:00:44.996 --> 00:00:47.306 modestly improved over the last four decades,

NOTE Confidence: 0.8521029

00:00:47.310 --> 00:00:49.823 I've chosen to invest a large bulk

NOTE Confidence: 0.8521029

00:00:49.823 --> 00:00:52.419 of a large bulk of my career.

NOTE Confidence: 0.8521029

00:00:52.420 --> 00:00:55.044 In trying to meet this challenge and have

NOTE Confidence: 0.8521029

00:00:55.044 --> 00:00:58.212 developed a team here at Yale called the

NOTE Confidence: 0.8521029

00:00:58.212 --> 00:00:59.844 Yale Pancreatic Cancer Collaborative.

NOTE Confidence: 0.8521029

00:00:59.850 --> 00:01:02.046 Or Yale pack that brings together

NOTE Confidence: 0.8521029

00:01:02.046 --> 00:01:03.931 clinicians and researchers at various

NOTE Confidence: 0.8521029

00:01:03.931 --> 00:01:06.091 disciplines across Yale and is poised

NOTE Confidence: 0.8521029

00:01:06.091 --> 00:01:08.063 to make dramatic discoveries in

NOTE Confidence: 0.8521029

00:01:08.063 --> 00:01:10.138 basic biology of pancreatic cancer,

NOTE Confidence: 0.8521029

00:01:10.140 --> 00:01:12.045 which will translate to improved

NOTE Confidence: 0.8521029

00:01:12.045 --> 00:01:13.569 therapies for our patients.

NOTE Confidence: 0.8521029

00:01:13.570 --> 00:01:16.610 Our lab studies the basic biology of KRAS,

NOTE Confidence: 0.8521029

00:01:16.610 --> 00:01:19.277 which is mutated in more than 90%

NOTE Confidence: 0.8521029

00:01:19.280 --> 00:01:20.321 of pancreatic cancers,

NOTE Confidence: 0.8521029

00:01:20.321 --> 00:01:22.750 and our work is uncovering new ways

NOTE Confidence: 0.8521029

00:01:22.810 --> 00:01:24.458 of targeting pancreatic cancers

NOTE Confidence: 0.8521029

00:01:24.458 --> 00:01:26.518 that harbor care as mutations,

NOTE Confidence: 0.8521029

00:01:26.520 --> 00:01:28.704 and also to identify drug combinations

NOTE Confidence: 0.8521029

00:01:28.704 --> 00:01:31.030 that can be used effectively.

NOTE Confidence: 0.8521029

00:01:31.030 --> 00:01:32.700 With new care as inhibitors

NOTE Confidence: 0.8521029

00:01:32.700 --> 00:01:34.370 that are entering the clinic.
NOTE Confidence: 0.8521029

00:01:34.370 --> 00:01:36.145 Our labs also interested in
NOTE Confidence: 0.8521029

00:01:36.145 --> 00:01:37.565 understanding the links between
NOTE Confidence: 0.8521029

00:01:37.565 --> 00:01:39.149 obesity and pancreatic cancer.
NOTE Confidence: 0.8521029

00:01:39.150 --> 00:01:41.358 Since obesity is a major risk
NOTE Confidence: 0.8521029

00:01:41.358 --> 00:01:42.830 factor for the disease,
NOTE Confidence: 0.8521029

00:01:42.830 --> 00:01:45.021 when I see patients at smilow Cancer
NOTE Confidence: 0.8521029

00:01:45.021 --> 00:01:47.294 Hospital on the inpatient service with
NOTE Confidence: 0.8521029

00:01:47.294 --> 00:01:49.826 pancreatic cancer or other solid tumors,
NOTE Confidence: 0.8521029

00:01:49.830 --> 00:01:52.030 I'm reminded of the challenges
NOTE Confidence: 0.8521029

00:01:52.030 --> 00:01:53.790 that our patients face.
NOTE Confidence: 0.8521029

00:01:53.790 --> 00:01:55.806 And when I it reinvigorates me to
NOTE Confidence: 0.8521029

00:01:55.806 --> 00:01:57.945 get back into the lab and work
NOTE Confidence: 0.8521029

00:01:57.945 --> 00:02:00.213 even harder to identify new ways of
NOTE Confidence: 0.8521029

00:02:00.213 --> 00:02:02.208 helping those patients through new
NOTE Confidence: 0.8521029

00:02:02.208 --> 00:02:04.140 approaches for treatment or prevention.